Cet anticorps anti-MEGF9 Polyclonal Lapin (ABIN7214686) détecte spécifiquement MEGF9 dans WB et ELISA.
L’anticorps est réactif avec des échantillons de Humain, Souris et Rat.
MEGF9
Reactivité: Humain
WB, ELISA, IHC
Hôte: Lapin
Polyclonal
APC
Indications d'application
Optimal working dilutions should be determined experimentally by the investigator. Suggested starting dilutions are as follows: WB 1:500-1:2000,ELISA 1:40000,Not yet tested in other applications.
Restrictions
For Research Use only
Format
Liquid
Concentration
1 mg/mL
Buffer
Liquid in PBS containing 50 % glycerol, 0.5 % BSA and 0.02 % sodium azide.
Agent conservateur
Sodium azide
Précaution d'utilisation
This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
Stock
-20 °C
Stockage commentaire
Stable for one year at -20°C from date of shipment. For maximum recovery of product, centrifuge the original vial after thawing and prior to removing the cap. Aliquot to avoid repeated freezing and thawing.
Date de péremption
12 months
Antigène
MEGF9
(Multiple EGF-Like-Domains 9 (MEGF9))
Autre désignation
EGFL5
Sujet
MEGF9, EGFL5, KIAA0818, Multiple epidermal growth factor-like domains protein 9, Multiple EGF-like domains protein 9, Epidermal growth factor-like protein 5, EGF-like protein 5MEGF9 (Multiple EGF-like domains protein 9, also EGF-like protein 5) is a 63 kDa (predicted) novel transmembrane glycoprotein that shares some homology to beta -chains of laminin. It is expressed by hepatocytes, cerebellar Purkinje cells, Schwann cells, keratinocytes and intestinal epithelium. MEGF9 is suggested to participate in cell motility, and its absence correlates with tumor cell migration. Mature human MEGF9 is 572 amino acids (aa) in length. It is a single span type I transmembrane protein that contains a 484 aa extracellular region (aa 31-514) plus a 68 aa C-terminal cytoplasmic domain. The extracellular region possesses a lengthy Pro-rich region (aa 55-200), followed by five EGF-like domains (aa 204-451). MEGF9 may run at approximately 160 kDa in SDS-PAGE, suggesting either heavy glycosylation or dimerization. Over aa 36-514, human MEGF9 shares 76 % aa sequence identity with mouse MEGF9.